Research Center Home | Contact | CHU Inside Map | Member's space | Français
About the Center Research Axes Researchers Clinical Research Services Students Chairs & Networks Communications Careers
You are here: › Research Center  › Our Researchers › KRAJINOVIC , Maja
Our Researchers
Our Postdoctorands
 › Our Researchers
Research Axis
Research Theme
CHU Sainte-Justine
Service d'hémato-oncologie
3175 Chemin de la Côte Sainte-Catherine
Montréal  (QC), Canada
H3T 1C5
514 345-4931 #6259
514 345-4731
Career Summary, Research Topics and Interests


  • Full Professor, Departments of Pediatrics and Pharmacology, University of Montreal.


  • Postdoctoral Fellow, CHU Sainte-Justine Research Center, Charles Bruneau Cancer Center, Montreal, 1995-1998.
  • Postdoctoral Fellow, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, 1992-1994.
  • PhD in Molecular Biology, University of Belgrade, Yougoslavia, 1987-1991.
  • MSc in Medical Genetics, University of Belgrade, 1984-1986.
  • Medical training, License, University of Belgrade, 1982-1984.
  • MD, University of Belgrade, 1977-1982.

Research Interests

The majority of drugs are characterized by pharmacokinetic and pharmacodynamic variability, explaining response variation in patients treated with the standard dose of a medication. Such variability can explain sub-optimal responses to drugs such as adverse reactions or resistance to treatment, indicating a need to identify factors associated with variable drug effects. This will allow the development of individualized treatments with increased efficacy for resistant patients and will reduce drug side effects in patients who respond well.

Based on the hypothesis that the polymorphisms in genes which control drug action (candidate genes), contribute to inter-individual variability in response to medication, we have developed several pharmacogenetics projects. The major goals of these projects are: a) to understand the influence of candidate gene polymorphisms on drug action, protein function and disease outcome; b) to identify polymorphisms that have predictive value to resistance/toxicity patterns; and c) to provide the knowledge that will establish the grounds for personalized drug treatment. One of the pharmacogenetic projects addresses several antitumor drugs used in the treatment of acute lymphoblastic leukemia (ALL). ALL is the most frequent pediatric malignancy still associated with resistance to treatment and drug side effects, in spite of increased survival rates achieved over the last decades.

We are also analyzing three major classes of medications used in the treatment of childhood asthma. In light of the increasing incidence and severity of asthma in children, more accurate use of asthma medication may provide adequate control of asthma early in the disease process (during childhood) thus possibly preventing loss of lung function in adult life. We are also running two pilot projects: pharmacogenetics of valproic acid in patients with idiopathic generalized epilepsy (since 20% of children do not respond to this anti-seizure agent) and pharmacogenetics of busulfan, a key compound in conditioning myeloablative regimens for children undergoing hematopoietic stem cell transplantation. Busulfan has a narrow therapeutic index: high drug exposure leads to increased risk of hepatic veno-occlusive disease, while low drug exposure has been associated with higher risk of disease recurrence and graft failure, requiring therapeutic drug monitoring and drug dose adjustment.

We are also running a complementary project based on the novel technological approach aiming to develop a new generation of nucleic acid probes. These probes should allow discrimination among the targets with high sequence identity.

Pediatric asthma database and biobank of the CHU Sainte-Justine

Awards and Distinctions
  • National Researcher, Fonds de la recherche en santé du Québec (FRSQ), 2007-2011.

  • Senior Research Scholar, FRSQ, 2003-2007.

  • Junior 2 Research Scholar, FRSQ, 2001-2003.

  • Bourse Relève 2000, Faculty of Medicine, University of Montreal, 2000-2001.

  • Postdoctoral Fellowship, Fondation Centre de cancérologie Charles-Bruneau, 1995-1998.

  • Postdoctoral Fellowship, Telethon, Italy, 1992-1994.

Most Important Publications Selected by the Researcher
Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M,
DNA variants in dihydrofolate reductase gene and outcome in childhood ALL
Blood 2008  3692-3700.
Brukner I, Krajinovic M, Dascal A, Labuda D,
A protocol for the in vitro selection of specific oligonucleotide probes for high-resolution DNA typing
Nat Protoc 2007  2807-2814.
Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A,
Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis
Pharmacogenomics J 2005  374-380.
Costea I, Moghrabi A, Krajinovic M,
The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia
Pharmacogenetics 2003  577-580.
Krajinovic M, Costea I, Chiasson S,
Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia
Lancet 2002  1033-1034.
Publications reported to FRSQ

Legal advice. (C) 2007-2008 Centre de Recherche du CHU Sainte-Justine. All rights reserved.